Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 7/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31323743 | 0.87 | DDB1 (0.39) | DDB1CRBN | |
| SCHEMBL31584033 | 0.85 | KDM4E (0.42) | DDB1CRBNKDM4EMAPTTHRB | |
| SCHEMBL31134480 | 0.84 | DDB1 (0.45) | DDB1CRBNMAPTGPR119NAMPT | |
| SCHEMBL23538562 | 0.82 | DDB1 (0.55) | DDB1CRBNKDM4EMAPTTHRB | |
| SCHEMBL31323401 | 0.82 | DDB1 (0.56) | DDB1CRBNKDM4EMAPTTHRB | |
| SCHEMBL29946867 | 0.82 | DDB1 (0.54) | DDB1CRBNKDM4EMAPTTHRB | |
| SCHEMBL29264315 | 0.81 | DDB1 (0.53) | DDB1CRBNKDM4EMAPTTHRB | |
| SCHEMBL30688281 | 0.80 | DDB1 (0.43) | DDB1CRBNMAPTWNT3A | |
| SCHEMBL26848888 | 0.80 | DDB1 (0.43) | DDB1CRBNMAPTWNT3A | |
| SCHEMBL29930514 | 0.80 | DDB1 (0.41) | DDB1CRBNKDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | C4 THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| EP-4333899-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117580592-A | Compounds for targeting bruton's tyrosine kinase degradation | 渤健马萨诸塞州股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2022235945-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | DDB1 729/4885CRBN 166/4885KDM4E 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.